Literature DB >> 24659151

[Nailfold capillaroscopy].

M Geyer1, M Vasile, W Hermann.   

Abstract

Capillaroscopy is performed to evaluate the morphology, frequency and blood flow of nailfold capillaries as well as relevant extracapillary changes in rheumatic conditions. The main indication is the differentiation between primary and secondary Raynaud's phenomenon. Various rheumatic conditions show different and partially typical pathognomonic alterations of the microcirculation or capillary patterns. This simple, noninvasive, inexpensive and effective technique is well suited for early diagnosis, especially of connective tissue diseases. The specific significance is highest for systemic sclerosis which is the most frequently evaluated entity. The corresponding microscopic alterations allow stage-adapted conclusions concerning the acuity of inflammation to be formed. That is not the only reason why capillaroscopy represents an important tool in follow-up controls and together with other techniques, such as flow measurement by laser Doppler, further conclusions can be drawn.

Entities:  

Mesh:

Year:  2014        PMID: 24659151     DOI: 10.1007/s00393-013-1314-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  17 in total

Review 1.  Raynaud's phenomenon.

Authors:  J A Block; W Sequeira
Journal:  Lancet       Date:  2001-06-23       Impact factor: 79.321

Review 2.  Raynaud's phenomenon and the role of capillaroscopy.

Authors:  Maurizio Cutolo; Walter Grassi; Marco Matucci Cerinic
Journal:  Arthritis Rheum       Date:  2003-11

Review 3.  A growing need for capillaroscopy in rheumatology.

Authors:  Rossella De Angelis; Walter Grassi; Maurizio Cutolo
Journal:  Arthritis Rheum       Date:  2009-03-15

Review 4.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

5.  Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases.

Authors:  G Spencer-Green
Journal:  Arch Intern Med       Date:  1998-03-23

Review 6.  Recent achievements in the management of Raynaud's phenomenon.

Authors:  Magnus Baumhäkel; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

Review 7.  Capillarosecopic patterns in rheumatic diseases.

Authors:  Sara Cortes; Maurizio Cutolo
Journal:  Acta Reumatol Port       Date:  2007 Jan-Mar       Impact factor: 1.290

8.  Nailfold capillaroscopy abnormalities correlate with cutaneous and visceral involvement in systemic sclerosis patients.

Authors:  Lucy T Sato; Cristiane Kayser; Luís E C Andrade
Journal:  Acta Reumatol Port       Date:  2009 Apr-Jun       Impact factor: 1.290

Review 9.  The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

10.  Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Authors:  Florian M P Meier; Klaus W Frommer; Robert Dinser; Ulrich A Walker; Laszlo Czirjak; Christopher P Denton; Yannick Allanore; Oliver Distler; Gabriela Riemekasten; Gabriele Valentini; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

View more
  3 in total

1.  [34/m-White and numb fingers : Preparation for the medical specialist examination: part 29].

Authors:  K S Mühlberg
Journal:  Internist (Berl)       Date:  2021-03-22       Impact factor: 0.743

Review 2.  [Capillary microscopy].

Authors:  W Hermann
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

3.  [Nailfold capillaroscopy-Principles and clinical application].

Authors:  R Hasseli-Fräbel; W Hermann; O Sander; K Triantafyllias
Journal:  Z Rheumatol       Date:  2022-04-21       Impact factor: 1.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.